Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Retained Earnings (2016 - 2024)

Historic Retained Earnings for Protalix BioTherapeutics (PLX) over the last 16 years, with Q4 2024 value amounting to -$378.4 million.

  • Protalix BioTherapeutics' Retained Earnings rose 82.72% to -$378.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$378.4 million, marking a year-over-year increase of 82.72%. This contributed to the annual value of -$378.4 million for FY2024, which is 82.72% up from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Retained Earnings of -$378.4 million as of Q4 2024, which was up 82.72% from -$381.5 million recorded in Q4 2023.
  • In the past 5 years, Protalix BioTherapeutics' Retained Earnings ranged from a high of -$347.4 million in Q4 2020 and a low of -$389.9 million during Q4 2022
  • For the 5-year period, Protalix BioTherapeutics' Retained Earnings averaged around -$374.4 million, with its median value being -$378.4 million (2024).
  • Its Retained Earnings has fluctuated over the past 5 years, first crashed by 794.06% in 2021, then surged by 213.2% in 2023.
  • Over the past 5 years, Protalix BioTherapeutics' Retained Earnings (Quarter) stood at -$347.4 million in 2020, then decreased by 7.94% to -$374.9 million in 2021, then fell by 3.98% to -$389.9 million in 2022, then increased by 2.13% to -$381.5 million in 2023, then grew by 0.83% to -$378.4 million in 2024.
  • Its Retained Earnings stands at -$378.4 million for Q4 2024, versus -$381.5 million for Q4 2023 and -$389.9 million for Q4 2022.